Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan
{"title":"雷司美罗：首个针对MASH的疾病特异性治疗方法。","authors":"Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan","doi":"10.1155/ije/6430023","DOIUrl":null,"url":null,"abstract":"<p><p>In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction-Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor-beta (THR-β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO-NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.</p>","PeriodicalId":13966,"journal":{"name":"International Journal of Endocrinology","volume":"2025 ","pages":"6430023"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985219/pdf/","citationCount":"0","resultStr":"{\"title\":\"Resmetirom: The First Disease-Specific Treatment for MASH.\",\"authors\":\"Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan\",\"doi\":\"10.1155/ije/6430023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction-Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor-beta (THR-β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO-NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.</p>\",\"PeriodicalId\":13966,\"journal\":{\"name\":\"International Journal of Endocrinology\",\"volume\":\"2025 \",\"pages\":\"6430023\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985219/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/ije/6430023\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/ije/6430023","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Resmetirom: The First Disease-Specific Treatment for MASH.
In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction-Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor-beta (THR-β) agonist, specifically targets liver function to simulate localized hyperthyroidism, effectively reducing lipid accumulation and liver fibrosis without the systemic effects commonly associated with thyroid hormone therapy. Clinical trials, particularly the pivotal MAESTRO-NASH trial, have demonstrated significant improvements in liver health metrics, achieving primary endpoints by resolving MASH without worsening fibrosis and showing a favorable safety profile. This paper reviews the mechanism of action, efficacy, and safety of resmetirom, providing insight into its potential to change the therapeutic landscape for patients suffering from MASH.
期刊介绍：
International Journal of Endocrinology is a peer-reviewed, Open Access journal that provides a forum for scientists and clinicians working in basic and translational research. The journal publishes original research articles, review articles, and clinical studies that provide insights into the endocrine system and its associated diseases at a genomic, molecular, biochemical and cellular level.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
